HALO — Halozyme Therapeutics Share News
0.000.00%
Last trade - 00:00- $13.79bn
- $15.71bn
- $1.40bn
Brief: Halozyme Therapeutics Says If Deal Is Terminated Under Certain Circumstances, Co To Pay Elektrofi Reverse Termination Fee Of $36 Million
U.S. RESEARCH ROUNDUP- Absci, Bloom Energy, Corteva
Halozyme to buy Elektrofi in up to $900 million deal to expand drug delivery lineup (updated)
Halozyme to buy Elektrofi for $750 million to expand drug delivery lineup
Halozyme Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Halozyme Therapeutics' Q2 revenue up 41%, beats estimates
Brief: European Commission Approved Darzalex Faspro For Adult Patients
Halozyme falls after Morgan Stanley downgrades
Halozyme Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Halozyme Announces Argenx Received Positive CHMP Opinion For Vyvgart (Efgartigimod Alfa) Subcutaneous Injection With Enhanze For CIDP
Halozyme sues Merck over new version of cancer drug; shares rise
Brief: Halozyme Sues Merck For Patent Infringement Over Subcutaneous Keytruda Formulation
Brief: European Commission Approved Subcutaneous Darzalex (Daratumumab) Based Quadruplet Regimen
Brief: European Commission Approves Subcutaneous Rybrevant® (Amivantamab)
Brief: Merck Says FDA PDUFA Date For Subcutaneous Pembrolizumab Set For Sept 23
Refile: Merck plans to launch US subcutaneous version of Keytruda on October 1
U.S. STOCKS ON THE MOVE-Moderna, Hims & Hers Health, Carrier
Halozyme climbs after report co to challenge Merck over patent infringement
New version of Merck's cancer drug faces possible patent battle, WSJ reports (updated)